Sugi Predict

Sugi Predict / Compounds / Phosphonic Acid

Phosphonic Acid

Phosphonic Acid

SCHEMBL1191561

CC(C)CC(C(=O)O)N(Cl)Cl.O=[PH](O)O

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RNPEP Q9H4A4 1/20 0.39
▸ SLC7A5 Q01650 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ CPA1 P15085 2/20 0.36
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ ALDH1A1 P00352 2/20 0.34
▸ SLC1A3 P43003 2/20 0.34
▸ SLC1A2 P43004 2/20 0.34
▸ MME P08473 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SLC1A1 P43005 1/20 0.32
▸ MMP1 P03956 1/20 0.31
▸ MMP3 P08254 1/20 0.31
▸ NR4A2 P43354 1/20 0.31
▸ CACNA2D1 P54289 2/20 0.31
▸ CACNB3 P54284 1/20 0.31
▸ CACNA1C Q13936 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphonic Acid SCHEMBL1191565 1.00 RNPEP (0.39) RNPEPSLC7A5MAPTCPA1CYP2D6
SCHEMBL3381425 0.92 RNPEP (0.44) RNPEPSLC7A5MAPTCPA1CYP2D6
SCHEMBL3381426 0.92 RNPEP (0.44) RNPEPSLC7A5MAPTCPA1CYP2D6
SCHEMBL1191884 0.86 RNPEP (0.40) RNPEPSLC7A5MAPTCPA1CYP2D6
SCHEMBL1191879 0.86 RNPEP (0.40) RNPEPSLC7A5MAPTCPA1CYP2D6
Phosphonic Acid SCHEMBL3379134 0.85 RNPEP (0.36) RNPEPSLC7A5MAPTCPA1ALDH1A1
Phosphonic Acid SCHEMBL3379130 0.85 RNPEP (0.36) RNPEPSLC7A5MAPTCPA1ALDH1A1
SCHEMBL3379157 0.75 RNPEP (0.41) RNPEPSLC7A5MAPTCPA1CYP2D6
SCHEMBL3379156 0.75 RNPEP (0.41) RNPEPSLC7A5MAPTCPA1CYP2D6
SCHEMBL22383970 0.74 SLC7A5 (0.50) RNPEPSLC7A5MAPTCPA1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140227201-A1 Antimicrobial Gel Formulations NOVABAY PHARMACEUTICALS, INC. 2014-08-14 — — US claimed
US-20110151025-A1 Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections NOVABAY PHARMACEUTICALS, INC. 2011-06-23 — — US claimed
EP-2265267-A1 COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS NovaBay Pharmaceuticals, Inc. (US) 2010-12-29 — — EP claimed
US-20100272783-A1 Methods of Treating Infections of the Nail NOVABAY PHARMACEUTICALS, INC. 2010-10-28 — — US claimed
US-20100076089-A1 ANTIMICROBIAL GEL FORMULATIONS NOVABAY PHARMACEUTICALS, INC. 2010-03-25 — — US claimed
WO-2009126912-A1 COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS NOVABAY PHARMACEUTICALS, INC. (US) 2009-10-15 — — WO claimed
EP-2265267-B1 COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS GOTTARDI WALDEMAR (AT) 2016-09-21 — — EP disclosed
US-20140227201-A1 Antimicrobial Gel Formulations NOVABAY PHARMACEUTICALS, INC. 2014-08-14 — — US disclosed
US-20110151025-A1 Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections NOVABAY PHARMACEUTICALS, INC. 2011-06-23 — — US disclosed
US-7893109-B2 N,N-dihalogenated amino acids and derivatives NOVABAY PHARMACEUTICALS, INC. (US) 2011-02-22 — — US disclosed
EP-2265267-A1 COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS NovaBay Pharmaceuticals, Inc. (US) 2010-12-29 — — EP disclosed
US-20100272783-A1 Methods of Treating Infections of the Nail NOVABAY PHARMACEUTICALS, INC. 2010-10-28 — — US disclosed
US-20100076089-A1 ANTIMICROBIAL GEL FORMULATIONS NOVABAY PHARMACEUTICALS, INC. 2010-03-25 — — US disclosed
WO-2010017405-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN HELLER ADAM (US) 2010-02-11 — — WO disclosed
WO-2009126912-A1 COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS NOVABAY PHARMACEUTICALS, INC. (US) 2009-10-15 — — WO disclosed
US-20090023812-A1 N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES NOVABAY PHARMACEUTICALS, INC. 2009-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023812-A1 N,N-DIHALOGENATED AMINO ACIDS AND DERIVATIVES DAO, DDC, NRDC RNPEP 323/4885SLC7A5 405/4885MAPT 2353/4885
US-20100272783-A1 Methods of Treating Infections of the Nail POLR1C, TYR, NACA RNPEP 373/4885SLC7A5 1281/4885MAPT 1469/4885
US-20140227201-A1 Antimicrobial Gel Formulations CUTA, TUBA3C, POLR1C RNPEP 2733/4885SLC7A5 2693/4885MAPT 1080/4885
US-20110151025-A1 Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections CFTR, NAT1, ELANE RNPEP 503/4885SLC7A5 200/4885MAPT 3713/4885
US-20100076089-A1 ANTIMICROBIAL GEL FORMULATIONS CUTA, TUBA3C, POLR1C RNPEP 2733/4885SLC7A5 2693/4885MAPT 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.